Worldwide Clinical Trials Hires Veteran CRO Business Development Leader to Further Accelerate Company Success

Chris Hill, with Proven Experience Impacting High Growth Companies, 
Joins as Senior Vice President of Business Development

Worldwide Clinical Trials, Inc. (Worldwide), an award-winning, full-service CRO, today announced the addition of Chris Hill as its new Senior Vice President, International Business Development. Hill brings strong operational insight into the nuances and challenges of a wide range of clinical studies – from cutting-edge early phase gene therapy to real-world evidence and patient registries – along with proven expertise helping companies achieve accelerated growth in competitive market segments.

Hill is Worldwide’s latest high-profile hire in recent months. Last week, Worldwide announced the company hired ex-Chiltern executive Sara Davis as Senior Vice President, Business Development, for the U.S. region.

Hill joins Worldwide with more than 25 years in the CRO and pharmaceutical industry. Most recently, he led strategic business development for Syneos Health (previously INC Research / inVentiv Health). Among his successes, Hill expanded business models and built strategic and trusted relationships across a broad network of biopharmaceutical and pharmaceutical leaders for Parexel International, Theorem Clinical Research, Quanticate and LCG Bioscience, among others.

“We are delighted to welcome Chris and his leadership capabilities to Worldwide at a time of great opportunity. Market insight shows that emerging to midsize pharmaceutical and biopharmaceutical organizations are seeking to avoid the trap of large CRO consolidation and commoditization,” said Peter Benton, president and COO, Worldwide Clinical Trials. “More and more are opting to partner instead with a midsize CRO like Worldwide because of our focus on delivering uncommon customer service and flexibility. Chris brings the unique blend of industry experience and knowledge we need to continue to build relationships with, and cater to, the specialized demands of our market.”

“I am thrilled to join Worldwide at such a pivotal time for the company and the pharmaceutical industry,” said Hill. “Worldwide is incredibly well placed to deliver the speed, quality and exceptional service emerging and midsized pharmaceutical and biopharmaceutical organizations demand of their CRO partner, and I’m looking forward to fully engaging with them to deliver better, faster and less expensive clinical research.”